Cosmo Pharmaceuticals NV
SIX:COPN

Watchlist Manager
Cosmo Pharmaceuticals NV Logo
Cosmo Pharmaceuticals NV
SIX:COPN
Watchlist
Price: 109 CHF 3.42% Market Closed
Market Cap: 1.9B CHF

Relative Value

The Relative Value of one COPN stock under the Base Case scenario is hidden CHF. Compared to the current market price of 109 CHF, Cosmo Pharmaceuticals NV is hidden .

Relative Value is the estimated value of a stock based on various valuation multiples like P/E and EV/EBIT ratios. It offers a quick snapshot of a stock's valuation in relation to its peers and historical norms.

COPN Relative Value
HIDDEN
Show
Worst Case
Base Case
Best Case

Valuation Multiples

vs History
46
vs Industry
26
Median 3Y
7
Median 5Y
9.9
Industry
2.6
Forward
13.3
vs History
28
vs Industry
34
Median 3Y
20.5
Median 5Y
20.3
Industry
21.4
Forward
65.9
vs History
55
vs Industry
42
Median 3Y
18.4
Median 5Y
30.3
Industry
16.4
vs History
26
vs Industry
7
Median 3Y
15.5
Median 5Y
5.2
Industry
22.8
vs History
0
vs Industry
40
Median 3Y
2.2
Median 5Y
2.2
Industry
2.2
vs History
44
vs Industry
28
Median 3Y
5.5
Median 5Y
9.2
Industry
2.9
Forward
12.3
vs History
50
vs Industry
36
Median 3Y
8.1
Median 5Y
14
Industry
5.5
vs History
49
vs Industry
38
Median 3Y
13.4
Median 5Y
22.9
Industry
13
Forward
64.2
vs History
41
vs Industry
39
Median 3Y
16.2
Median 5Y
23.2
Industry
16.5
Forward
51.7
vs History
49
vs Industry
45
Median 3Y
13.9
Median 5Y
23.1
Industry
15.6
vs History
53
vs Industry
34
Median 3Y
18.5
Median 5Y
29.6
Industry
18.7
vs History
0
vs Industry
41
Median 3Y
1.9
Median 5Y
2
Industry
1.9

Multiples Across Competitors

COPN Competitors Multiples
Cosmo Pharmaceuticals NV Competitors

All Multiples
P/S
P/E
EV/EBITDA
EV/EBIT
All Countries
Close
Market Cap P/S P/E EV/EBITDA EV/EBIT
IE
Cosmo Pharmaceuticals NV
SIX:COPN
1.7B CHF 10.3 34 23.8 28.7
US
Eli Lilly and Co
NYSE:LLY
1T USD 17.5 56.4 37.8 40.5
UK
Dechra Pharmaceuticals PLC
LSE:DPH
440.4B GBP 578.3 -15 783.5 3 846.3 17 702.3
US
Johnson & Johnson
NYSE:JNJ
497.7B USD 5.4 19.8 16.2 21
CH
Roche Holding AG
SIX:ROG
269.3B CHF 4.4 28.6 12.2 14.2
UK
AstraZeneca PLC
LSE:AZN
220.6B GBP 5.1 31.7 108.8 159.2
US
Merck & Co Inc
NYSE:MRK
269.9B USD 4.2 14.2 10 11.9
CH
Novartis AG
SIX:NOVN
218B CHF 4.9 19 12 15.6
DK
Novo Nordisk A/S
CSE:NOVO B
1.6T DKK 5.2 15.7 10.9 12.7
IE
Endo International PLC
LSE:0Y5F
213.9B USD 92.2 -73.2 338.7 849.2
US
Pfizer Inc
NYSE:PFE
143.2B USD 2.3 14.6 7.4 10.2
P/E Multiple
Earnings Growth PEG
IE
Cosmo Pharmaceuticals NV
SIX:COPN
Average P/E: 26
34
-34%
N/A
US
Eli Lilly and Co
NYSE:LLY
56.4
54%
1
UK
Dechra Pharmaceuticals PLC
LSE:DPH
Negative Multiple: -15 783.5 N/A N/A
US
Johnson & Johnson
NYSE:JNJ
19.8
29%
0.7
CH
Roche Holding AG
SIX:ROG
28.6
29%
1
UK
AstraZeneca PLC
LSE:AZN
31.7
37%
0.9
US
Merck & Co Inc
NYSE:MRK
14.2
15%
0.9
CH
Novartis AG
SIX:NOVN
19
17%
1.1
DK
Novo Nordisk A/S
CSE:NOVO B
15.7
3%
5.2
IE
E
Endo International PLC
LSE:0Y5F
Negative Multiple: -73.2 N/A N/A
US
Pfizer Inc
NYSE:PFE
14.6
27%
0.5
EV/EBITDA Multiple
EBITDA Growth EV/EBITDA to Growth
IE
Cosmo Pharmaceuticals NV
SIX:COPN
Average EV/EBITDA: 402.2
23.8
-24%
N/A
US
Eli Lilly and Co
NYSE:LLY
37.8
34%
1.1
UK
Dechra Pharmaceuticals PLC
LSE:DPH
3 846.3
36%
106.8
US
Johnson & Johnson
NYSE:JNJ
16.2
9%
1.8
CH
Roche Holding AG
SIX:ROG
12.2
5%
2.4
UK
AstraZeneca PLC
LSE:AZN
108.8
10%
10.9
US
Merck & Co Inc
NYSE:MRK
10
6%
1.7
CH
Novartis AG
SIX:NOVN
12
6%
2
DK
Novo Nordisk A/S
CSE:NOVO B
10.9
1%
10.9
IE
E
Endo International PLC
LSE:0Y5F
338.7
N/A N/A
US
Pfizer Inc
NYSE:PFE
7.4
0%
N/A
EV/EBIT Multiple
EBIT Growth EV/EBIT to Growth
IE
Cosmo Pharmaceuticals NV
SIX:COPN
Average EV/EBIT: 1 715
28.7
-36%
N/A
US
Eli Lilly and Co
NYSE:LLY
40.5
36%
1.1
UK
Dechra Pharmaceuticals PLC
LSE:DPH
17 702.3
98%
180.6
US
Johnson & Johnson
NYSE:JNJ
21
15%
1.4
CH
Roche Holding AG
SIX:ROG
14.2
6%
2.4
UK
AstraZeneca PLC
LSE:AZN
159.2
23%
6.9
US
Merck & Co Inc
NYSE:MRK
11.9
8%
1.5
CH
Novartis AG
SIX:NOVN
15.6
12%
1.3
DK
Novo Nordisk A/S
CSE:NOVO B
12.7
0%
N/A
IE
E
Endo International PLC
LSE:0Y5F
849.2
N/A N/A
US
Pfizer Inc
NYSE:PFE
10.2
7%
1.5